Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Continuous clopidogrel therapy may lead to delayed and immediate bleeding after polypectomy, though only to a nonsignificant degree, reports a recent study.
Adequate tea drinking (<240 ml/day or 19 cup-years) may help lower the risk of gallstones in both men and women, a recent Taiwan study has shown.
Elderly, vulnerable patients with metastatic colorectal cancer (CRC) experienced longer progression-free survival (PFS) and fewer toxicities with a reduced-dose combination chemotherapy regimen of S-1 and oxaliplatin compared with full-dose S-1 monotherapy, the phase II NORDIC9* trial showed.
Combination treatment with glecaprevir plus pibrentasvirproduces a sustained virological response in more than 90 percent of hepatitis C virus (HCV)-infected patients who previously failed direct-acting antiviral (DAA) treatments, regardless of liver fibrosis stage, a study has shown.
A recent study has shown that the short-term efficacy of tenofovir disoproxil fumarate (TDF) is superior to entecavir (ETV) for the treatment of acute-on-chronic-liver failure (ACLF) due to reactivation of chronic hepatitis B (CHB).
Gastrointestinal (GI) symptom severity and anxiety are associated with the physical component score (PCS), while psychosocial and somatic measures correlate with the mental component score in irritable bowel syndrome (IBS), reports a recent study. Health-related quality of life (HRQOL), however, is similar in IBS patients and healthy controls when perceived stress, somatic symptom severity and mindfulness are at optimal levels.
A recent study has identified multiple comorbidities that increase the risk of 30-day readmission for diverticular haemorrhage, which stands at 12 percent.
Special Reports
There is an increasing number of studies that shed light on the importance of our gut microbiota. Probiotics are live microorganisms that confer health benefits on the host when administered in adequate amounts. With new data emerging about their proposed benefits in maintaining intestinal health, probiotics continue to gain popularity amongst consumers.
Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.
Last August, the article 'Role of General Practitioners in Early Detection of Inflammatory Bowel Disease' highlighted proper screening and early specialist referral by the general practitioner (GP) as vital components in reducing the burden of inflammatory bowel disease (IBD). This year, the focus is on the role of GPs in co-managing a patient with IBD at the follow-up phase.
Nonalcoholic fatty liver disease (NAFLD), including simple steatosis and nonalcoholic steatohepatitis (NASH), is widely considered as the liver manifestation of the metabolic syndrome. It is a major cause of liver disease worldwide and its prevalence is expected to rise in tandem with the rising prevalence of obesity and diabetes mellitus. Recently, MIMS Doctor spoke to Associate Professor Dr Wah Kheong Chan, a Consultant Physician and Gastroenterologist at the University of Malaya Medical Centre and University of Malaya Specialist Centre, to provide an update on NAFLD, with a particular emphasis on the use of silymarin for the treatment of NASH. Here are the highlights from the interview.
Constipation is a common disorder which adversely affects the wellbeing and quality of life of patients.1 Recently, MIMS Doctor spoke to Associate Prof Dr Raja Affendi Raja Ali on the landscape of constipation in Malaysia, emphasizing on effective and early management of the condition.
DUKORAL – Inactivated Vibrio cholerae O1 serogroup & recombinant cholera toxin B subunit (WC/rCTB) vaccine (oral) – AJ Biologics
At the recent Asian Pacific Digestive Week (APDW) 2016 held in Kobe, Japan, three prominent international experts shared their views on gastroesophageal reflux disease (GERD) and the challenges of its management.
Conference Reports
Joint pain is the most common extraintestinal manifestation (EIM) of inflammatory bowel disease (IBD), according to a presentation during AIBD 2018.
The favourable safety profile of vedolizumab in patients with inflammatory bowel disease (IBD) persists even in real-world clinical practice, according to the first 4 years of post-marketing safety data reported at AIBD 2018.
The incidence of Clostridium difficile (C. difficile) infection among patients with ulcerative colitis (UC) who are receiving treatment with tofacitinib is low and particularly so when compared with C. difficile infection incidence in patients receiving other UC therapies, according to a poster presented at AIBD 2018.
Patients with paediatric-onset inflammatory bowel disease (pIBD) have a higher incidence of severe IBD than those with adult-onset IBD (aIBD), according to a study presented at AIBD 2018.
Older patients receiving treatment for ulcerative colitis (UC) were more likely to experience adverse events (AEs) compared with their younger counterparts, according to a study presented at AIBD 2018.
Patients with obesity have an elevated risk of intra- and postoperative complications following surgical treatment for inflammatory bowel disease (IBD), according to a presentation at the recent Advances in Inflammatory Bowel Disease meeting (AIBD 2018).
The α4β7 integrin antibody vedolizumab continues to show efficacy and safety in patients with inflammatory bowel disease (IBD) in an era beyond tumour necrosis factor (TNF) inhibitors, according to a presentation at the annual Advances in Inflammatory Bowel Diseases (AIBD) 2018 meeting.
.jpg)
